EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists

Kanchan Dongre, Yasmin Schmid, Luana Nussbaum, Clemens Winterhalder, Stefano Bassetti, Andreas Holbro, Lukas Degen, Anne B Leuppi-Taegtmeyer

Global Cardiology Science and Practice · 10.12.2022 · 2022 (3)

DOI: 10.21542/gcsp.2022.21 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Cardiology Science and Practice, online erschienen am 10.12.2022. Verfasst von Kanchan Dongre und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Patient Safety, Medical Directorate, University Hospital Basel, Switzerland. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Patients receiving oral anticoagulants with vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) have an increased risk of gastrointestinal bleeding (GIB). We compared cases of GIB associated with VKAs and DOACs in terms of risk factors, scores, timing, location, severity, and outcome.

Methods

Data from patients treated at a university hospital in Switzerland for GIB under VKA and DOACs between 2012 and 2018 were analyzed in this investigator-driven, retrospective, single-center study.

Results

A total of 248 patients (110 males; median age, 80 years; 134 VKA, 114 DOAC) were included. No significant differences in age, weight or sex were observed. The propensity of the VKA group for risk factors such as comorbidities, interacting medications, or a high risk for bleeding (HAS-BLED score) was higher than that of the DOAC group. 56% of the VKA-treated patients had a supratherapeutic INR, and 25% in the DOAC group received an unlicensed dose. Significantly more patients in the DOAC group were not formally overdosed with OAC whilst receiving amiodarone compared to the VKA group (57% vs. 18%, respectively, p = 0.03). Latency between the documented start of oral anticoagulation and GIB was shorter in the DOAC group (median 3 months) than in the VKA group (median 23.5 months, p

Autor:innen und Institutionen

  • Department of Patient Safety, Medical Directorate, University Hospital Basel, Switzerland.
  • Department of Clinical Pharmacology and Toxicology, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Division of Internal Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Blood Transfusion Centre, Swiss Red Cross, Basel, Switzerland.
  • Department of Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Clarunis, University Center for Gastrointestinal and Liver Diseases, Basel, Switzerland.

Zitieren

APA

Dongre, K., Schmid, Y., Nussbaum, L., Winterhalder, C., Bassetti, S., Holbro, A., Degen, L., & Leuppi-Taegtmeyer, A. B. (2022). Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists. Global Cardiology Science and Practice, 2022(3). https://doi.org/10.21542/gcsp.2022.21

Vancouver

Dongre K, Schmid Y, Nussbaum L, Winterhalder C, Bassetti S, Holbro A, et al. Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists. Global Cardiology Science and Practice. 2022;2022(3). doi:10.21542/gcsp.2022.21

BibTeX
@article{Dongre2022,
  author = {Dongre, Kanchan and Schmid, Yasmin and Nussbaum, Luana and Winterhalder, Clemens and Bassetti, Stefano and Holbro, Andreas and Degen, Lukas and Leuppi-Taegtmeyer, Anne B},
  title = {Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists},
  journal = {Global Cardiology Science and Practice},
  year = {2022},
  volume = {2022},
  number = {3},
  doi = {10.21542/gcsp.2022.21}
}
Kostenlos starten →